A Study of the Epidemiology and Hospital Management of Patients With PROS in France

Epidemiology and Hospital Management of Patients With PROS in France: a PMSI Study

The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from the French National Hospitals Database, Programme de Médicalisation des Systèmes d'Information (PMSI). The study period was from January 2015 to December 2022.

Inclusion criteria:

Population P1 was identified using a combined query, considering:

• International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes for PROS-related malformations; OR
• PROS-related technical procedures performed during hospitalizations to relieve the symptoms of the disease.

Subpopulation SP1 was identified through the identification of at least two PROS-related hospitalizations (PROS-related ICD-10-CM or technical procedure code), including the index hospitalization.

Exclusion criteria:

Presence at any time during the entire study period of:

• ICD-10-CM codes for chromosomal malformation; OR
• ICD-10-CM code for hemangioma to avoid inclusion of patients with hemangioma and other vascular malformation; OR
• ICD-10-CM codes associated with the following comorbidities: cancer, cerebrovascular pathologies, hemiplegia (for pediatric patients only), metastatic pathologies, or myocardial infarction.